JP2008514925A - 腫瘍を検出し且つ治療するための組成物及び方法 - Google Patents

腫瘍を検出し且つ治療するための組成物及び方法 Download PDF

Info

Publication number
JP2008514925A
JP2008514925A JP2007533654A JP2007533654A JP2008514925A JP 2008514925 A JP2008514925 A JP 2008514925A JP 2007533654 A JP2007533654 A JP 2007533654A JP 2007533654 A JP2007533654 A JP 2007533654A JP 2008514925 A JP2008514925 A JP 2008514925A
Authority
JP
Japan
Prior art keywords
ephb4
cell
tumor
gene
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007533654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008514925A5 (https=
Inventor
レディ ラマチャンドラ
ギル パルカシュ
Original Assignee
バスジーン セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バスジーン セラピューティクス， インコーポレイテッド filed Critical バスジーン セラピューティクス， インコーポレイテッド
Publication of JP2008514925A publication Critical patent/JP2008514925A/ja
Publication of JP2008514925A5 publication Critical patent/JP2008514925A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007533654A 2004-09-23 2005-09-23 腫瘍を検出し且つ治療するための組成物及び方法 Abandoned JP2008514925A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61286104P 2004-09-23 2004-09-23
PCT/US2005/034179 WO2006034456A2 (en) 2004-09-23 2005-09-23 Compositions and methods for detecting and treating tumors

Publications (2)

Publication Number Publication Date
JP2008514925A true JP2008514925A (ja) 2008-05-08
JP2008514925A5 JP2008514925A5 (https=) 2008-11-13

Family

ID=36090700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007533654A Abandoned JP2008514925A (ja) 2004-09-23 2005-09-23 腫瘍を検出し且つ治療するための組成物及び方法

Country Status (6)

Country Link
US (1) US20060194220A1 (https=)
EP (1) EP1799867A2 (https=)
JP (1) JP2008514925A (https=)
AU (1) AU2005286663A1 (https=)
CA (1) CA2581430A1 (https=)
WO (1) WO2006034456A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011169873A (ja) * 2010-02-22 2011-09-01 Nagasaki Univ 癌転移の検出方法および検出用キット
JP2019529959A (ja) * 2016-09-30 2019-10-17 サルフィー，デイビッド 癌の再発および進行のモニタリング
JP2021531790A (ja) * 2018-07-27 2021-11-25 ベンタナ メディカル システムズ， インコーポレイテッド 自動化された原位置ハイブリッド形成分析のためのシステム
JP2021193897A (ja) * 2020-06-10 2021-12-27 国立大学法人東京農工大学 イヌ中皮腫細胞株

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070218061A1 (en) * 2005-09-23 2007-09-20 Vasgene Therapeutics, Inc. Use of ephrinb2 directed agents for the treatment or prevention of viral infections
US20070292882A1 (en) * 2006-06-16 2007-12-20 Sysmex Corporation Method and apparatus for detecting cancer cell
JP2008289456A (ja) * 2006-06-16 2008-12-04 Sysmex Corp がん細胞の検出方法及び装置
US7662566B2 (en) * 2006-11-22 2010-02-16 Myriad Genetics, Inc. Gene copy number profiling
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
ES2386495T3 (es) * 2007-11-29 2012-08-21 Molecular Health Gmbh siARN específico de EPH-B4 para reducir el crecimiento de células neoplásicas inducidas por EPO durante el tratamiento de anemia en pacientes con cáncer, receptor de eritropoyetina protector de tejido (NEPOR) y métodos de uso
ES2832880T3 (es) * 2017-06-08 2021-06-11 Lumito Ab Un método de análisis de una muestra para al menos un analito
EP4105328A1 (en) * 2021-06-15 2022-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6331302B1 (en) * 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6303769B1 (en) * 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5864020A (en) * 1994-07-20 1999-01-26 Genentech, Inc. HTK ligand
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
CA2259157A1 (en) * 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
US6150162A (en) * 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
US6770633B1 (en) * 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
US6271030B1 (en) * 2000-06-14 2001-08-07 Isis Pharmaceuticals, Inc. Antisense inhibition of C/EBP beta expression
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2003004057A1 (en) * 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
US20040110150A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
EP1606305A4 (en) * 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011169873A (ja) * 2010-02-22 2011-09-01 Nagasaki Univ 癌転移の検出方法および検出用キット
JP2019529959A (ja) * 2016-09-30 2019-10-17 サルフィー，デイビッド 癌の再発および進行のモニタリング
JP7065862B2 (ja) 2016-09-30 2022-05-12 セロクソ リミテッド 癌の再発および進行のモニタリング
US11435341B2 (en) 2016-09-30 2022-09-06 Seroxo Limited Monitoring cancer recurrence and progression
JP2021531790A (ja) * 2018-07-27 2021-11-25 ベンタナ メディカル システムズ， インコーポレイテッド 自動化された原位置ハイブリッド形成分析のためのシステム
JP2023100730A (ja) * 2018-07-27 2023-07-19 ベンタナ メディカル システムズ， インコーポレイテッド 自動化された原位置ハイブリッド形成分析のためのシステム
US12020493B2 (en) 2018-07-27 2024-06-25 Ventana Medical Systems, Inc. Systems for automated in situ hybridization analysis
US12367692B2 (en) 2018-07-27 2025-07-22 Ventana Medical Systems, Inc. Systems for automated in situ hybridization analysis
JP2021193897A (ja) * 2020-06-10 2021-12-27 国立大学法人東京農工大学 イヌ中皮腫細胞株
JP7464977B2 (ja) 2020-06-10 2024-04-10 国立大学法人東京農工大学 イヌ中皮腫細胞株

Also Published As

Publication number Publication date
EP1799867A2 (en) 2007-06-27
WO2006034456A3 (en) 2006-08-10
US20060194220A1 (en) 2006-08-31
AU2005286663A1 (en) 2006-03-30
WO2006034456A2 (en) 2006-03-30
CA2581430A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
Zhang et al. Expression and functional characterization of ABCG2 in brain endothelial cells and vessels
EP1814909B1 (en) Use of aimp2dx2 for the diagnosis and treatment of cancer
JP5603145B2 (ja) 疾患のイメージング、診断、及び治療
CN103339265B (zh) 用于乳腺癌转移的诊断、预后和治疗的方法
US8846629B2 (en) Id-1 and Id-2 genes and products as therapeutic targets for treatment of breast cancer and other types of carcinoma
JP6534930B2 (ja) Ｎｔｒｋ３融合体の検出法
WO2005084109A2 (en) Cancer specific gene mh15
JPWO2013133351A1 (ja) 新規ｆｇｆｒ３融合体
JPWO2017122815A1 (ja) 新規融合体及びその検出法
JP2008514925A (ja) 腫瘍を検出し且つ治療するための組成物及び方法
CN101087804B (zh) 用于诊断和治疗癌症的aimp2dx2的用途
Kavsan et al. Characterization of genes with increased expression in human glioblastomas.
JPWO2017122816A1 (ja) 新規融合体及びその検出法
ES2684548T3 (es) Proteína de fusión que comprende AXL y composición para tratar el cáncer que comprende la misma
JPH08500731A (ja) 診断法
EP1829967A1 (en) Method of diagnosing malignant lymphoma and estimating the prognosis thereof
KR102025005B1 (ko) 전암성 병변에서 조기 간암을 진단 및 예측할 수 있는 바이오 마커 및 이의용도
JP6806440B2 (ja) 新規融合体及びその検出法
KR101808658B1 (ko) 암 진단 키트 및 암 예방 또는 치료용 약제학적 조성물
US20040138161A1 (en) Methods of modulating proliferative conditions
DE102005059242A1 (de) Molekulare Marker für eine Tumordiagnose und -therapie

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080924

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20100607